Investors & Media

2017 Press Releases

Webcast ImageWebcast
Flex Pharma Inc at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference (Replay)
03/21/17 at 10:55 a.m. ET
Flex Pharma Inc at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference
Tuesday, March 21, 2017 10:55 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
03/08/17Flex Pharma Reports Year End 2016 Financial Results
-- IND Submission for FLX-787 On Track for H1 2017 -- -- Phase 2 ALS & CMT Studies with FLX-787 Planned to Initiate This Year -- -- Successful Launch Year for HOTSHOT® Consumer Brand; Revenue Exceeds Expectations -- Conference Call Scheduled Today at 8:30 a.m. ET BOSTON--(BUSINESS WIRE)--Mar. 8, 2017-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovat... 
Printer Friendly Version
03/01/17Flex Pharma to Report Fourth Quarter and Full Year 2016 Results on March 8, 2017
BOSTON--(BUSINESS WIRE)--Mar. 1, 2017-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for cramps and spasms associated with the severe neurological diseases of ALS, MS and peripheral neuropathies such as Charcot-Marie-Tooth (CMT), announced today that it will report its financial results for the fourth quarter and year ended December 31, 2016 ... 
Printer Friendly Version
02/07/17Flex Pharma to Present at the BIO CEO & Investor Conference
BOSTON--(BUSINESS WIRE)--Feb. 7, 2017-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS) today announced that Company management will present a corporate overview at the 2017 BIO CEO & Investor Conference on Tuesday, February 14, 2017 at 10:00 a.m. A live webcast of Flex Pharma’s presentations at these conferences may be accessed in the Investor section of the Company’s website at www.flex-pharma.com. Please log on to the... 
Printer Friendly Version
01/24/17Flex Pharma Focuses on Phase 2 Clinical Programs in Severe Neurological Diseases
-- Additional Proof-of-Concept Phase 2 Studies Planned to Initiate in 2017 -- -- Exploratory Phase 2 MS Study Results by Year End 2017 -- BOSTON--(BUSINESS WIRE)--Jan. 24, 2017-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS) today announced that it is prioritizing its clinical programs in the severe neurological diseases of amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and peripheral ... 
Printer Friendly Version